Stephen Liu: FDA approves repotrectinib for NTRK fusion positive solid tumors

Stephen Liu recently shared a post on X:

“FDA approves repotrectinib for NTRK fusion positive solid tumors (tissue agnostic).

In TKI naive group, RR 58% and mDOR not reached.

With prior TKI, RR 50%, mDOR 9.9m.

Repotrectinib previously received approval for ROS1 NSCLC on 11/15/23.”

Additional information.
Source: Stephen Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.